| Management target | Revenue 25.0% FY27 |
|---|
| Revenue growth | 13.7% YoY growth in Q1 FY27. |
|---|---|
| Margins | EBITDA margin at 36.4%; moderated QoQ due to facility expenses and labor. |
| Order book | Healthy enquiries and orders in clinical research; first Biologics client onboarded. |
| Demand visibility | Positive enquiry trends in Pharma and Electronics; Biologics first order secured. |
| Management confidence | High; optimistic on maintaining growth momentum despite near-term regional headwinds. |
Growth
Revenue grew 13.7% YoY; EBITDA increased 16% to INR 411 million; PAT rose 11.4% to INR 210 million.
Outlook
FY27 capex budget of INR 80 crores. Management aims to maintain or exceed 20-25% growth momentum annually.
Risks
Global geopolitical challenges in the Middle East impacting food import/export volumes; currency appreciation and new labor laws.
Last quarter's promises, checked
Delivered
- Guided 35% EBITDA margin → delivered 36.4% (= BEAT)
- Guided entry into Biologics FY27 → delivered first order secured (= BEAT)
- Guided net debt-free status → delivered net debt-free (= BEAT)
Partly delivered
- Guided INR 500cr revenue run rate by Q4 FY26 → delivered INR 416.3cr FY26 (= PARTIAL)
Missed
- Guided 20-25% CAGR growth → delivered 13.7% YoY (= MISS)
Investor Presentation filed with NSE, NSE: VIMTALABS. Summary written with AI assistance from the document.
Vimta Labs Ltd: key numbers
- Share price
- ₹599.30
- Market cap
- ₹2,679 Cr
- Revenue (annual)
- ₹407.3 Cr
- Net profit (annual)
- ₹77.51 Cr
- P/E (TTM)
- 33.6×Sector 57.8×
- Promoter holding
- 35.67%-0.18% QoQ
- FII holding
- 4.41%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Vimta Labs Ltd
All →Vimta Labs Employee Stock Options
Vimta Labs allotted 12,955 ESOP shares under its 2021 plan. Paid-up capital rose to ₹8,93,99,718, raising dilution for shareholders.
Vimta Labs Credit Rating
CARE Ratings has reaffirmed the bank facility ratings of Vimta Labs Limited. The disclosure updates stakeholders on the company's ongoing credit facilities.
Vimta Labs Earnings Call: Key Takeaways
Vimta Labs reports 13.7% YoY revenue growth in Q1 FY27, driven by strong performance in Pharma and Food testing segments with a 36.4% EBITDA margin.
Vimta Labs Q1 FY27 Results: Net Profit ₹21 Cr, Up 11.1% YoY
Vimta Labs Ltd reported revenue from operations of ₹109.1 Cr (+11.8% YoY) and net profit of ₹21 Cr (+11.1% YoY) for Q1 FY27.
- Key figure
- Net profit ₹21 Cr · +11.1% YoY
Vimta Labs Earnings Call: Key Takeaways
Vimta Labs reported Q4 FY26 revenue of ₹1,120M (+16.6% YoY) and FY26 revenue of ₹4,163M (+19.5% YoY). Strategy focuses on core pharma/food testing and entry into biologics.
Vimta Labs Earnings Call: Key Takeaways
Vimta Labs reported Q4 FY26 revenue of ₹1,120 Mn and PAT of ₹211 Mn with strong margins across TIC segments.